McKenna Mark C.
CIK 0001749623
Chairman, President and CEODirector
Filings
18
Latest May 29, 2026
Issuers covered
5
Showing
18 of 18
Page 1
Track record
2 of 9 open-market trades scored (22% price coverage) - 7 issuers without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 2 | 0% | -7.7% | -7.7% | -7.7% | -7.7% |
| 90 days | 2 | 0% | -13.1% | -13.1% | -13.1% | -13.1% |
| 180 days | 2 | 0% | -5.2% | -5.2% | -5.2% | -5.2% |
| 365 days | 2 | 100% | +73.9% | +73.9% | +73.9% | +73.9% |
Issuers
Companies where McKenna Mark C. has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| RXDX | Prometheus Biosciences, Inc. | 7 | Jun 16, 2023 |
| APGE | Apogee Therapeutics, Inc. | 4 | Jun 20, 2025 |
| NAMS | Newamsterdam Pharma Co N.V. | 3 | Jan 9, 2026 |
| SYRE | Spyre Therapeutics, Inc. | 3 | May 29, 2026 |
| BBOT | Bridgebio Oncology Therapeutics, Inc. | 1 | Aug 11, 2025 |
All filings
18 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|